Author:
Othus M,Kantarjian H,Petersdorf S,Ravandi F,Godwin J,Cortes J,Pierce S,Erba H,Faderl S,Appelbaum F R,Estey E
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference15 articles.
1. Appelbaum F, Gundacker H, Head D, Slovak M, Willman C, Godwin J et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481–3485.
2. Walter R, Othus M, Borthakur G, Ravandi F, Cortes J, Pierce S et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011; 29: 4417–4423.
3. Estey E, Smith TL, Keating MJ, McCredie KB, Gehan EA, Freireich EJ . Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia 1989; 3: 257–263.
4. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109: 1114–1124.
5. Fenaux P, Mufti G, Hellström-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562–569.
Cited by
138 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献